Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647597 | 0.76 | — | — | |
| SCHEMBL2487140 | 0.76 | — | — | |
| SCHEMBL1902535 | 0.76 | — | — | |
| SCHEMBL6196835 | 0.76 | — | — | |
| SCHEMBL3552256 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL6201103 | 0.74 | ARG1 (0.36) | — | |
| Bromide SCHEMBL10467943 | 0.74 | ARG1 (0.36) | — | |
| SCHEMBL29974391 | 0.74 | — | — | |
| SCHEMBL359078 | 0.72 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL10039814 | 0.72 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250042843-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3000805-B1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3000805-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| CN-103936645-B | The tetracycline compound that C7-fluorine replaces | TETRAPHASE PHARMACEUTICALS INC. (US) | 2016-03-09 | — | — | CN | disclosed |
| CN-102177134-B | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS INC | 2014-04-16 | — | — | CN | disclosed |
| EP-2682387-A2 | C7-fluoro substituted tetracycline compounds | Tetraphase Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8501716-B2 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2323972-B1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| CN-102177134-A | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| EP-2323972-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| WO-2010017470-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20250042843-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | CBR1, CYP7A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPSR1 890/4885CYP4F2 92/4885CYP4A11 180/4885 |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NPSR1 4173/4885CYP4F2 84/4885CYP4A11 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.